Project: Blue Ivy iGEM Universitas Indonesia ? Tuberculosis? - - PowerPoint PPT Presentation

▶
project blue ivy
SMART_READER_LITE
LIVE PREVIEW

Project: Blue Ivy iGEM Universitas Indonesia ? Tuberculosis? - - PowerPoint PPT Presentation

Oct 12, 2022 294 likes •569 views

Project: Blue Ivy iGEM Universitas Indonesia ? Tuberculosis? Worldwide Infection, 2011 9 4 million million Source: http://www.cdc.gov/tb/statistics/ http://www.who.int/mediacentre/factsheets/fs211/en/ Worldwide Infection, 2011 Is it

slide-1
SLIDE 1

Project: Blue Ivy

iGEM Universitas Indonesia

slide-2
SLIDE 2

?

slide-3
SLIDE 3

Tuberculosis?

slide-4
SLIDE 4

Worldwide Infection, 2011

4 million

9 million

Source: http://www.cdc.gov/tb/statistics/ http://www.who.int/mediacentre/factsheets/fs211/en/

slide-5
SLIDE 5

Worldwide Infection, 2011

slide-6
SLIDE 6

Is it that hard to erradicate Tuberculosis?

slide-7
SLIDE 7

Present Detection Method

slide-8
SLIDE 8

Our System

slide-9
SLIDE 9

Our Target: Antigen 85

Ag 85 Ag 85 Ag 85 Ag 85 Ag 85 Ag 85 Ag 85 Ag 85

Sputum Blood serum Urine

slide-10
SLIDE 10

Our Device

Specific Detector Single Chain Variable Fragment of Antibody Flexible Linker Split Reporter Beta-galactosidase

slide-11
SLIDE 11

Antigen 85

slide-12
SLIDE 12

Why β-Galactosidase?

Well characterized Visible activity Cheaper substrate Longer signal

slide-13
SLIDE 13

Parts Characterization

Enzimatic Activity Assay

Incubation time (hours)

slide-14
SLIDE 14

Parts Characterization

Stability Assay of Beta-Galactosidase

The enzyme stored in 4oC

Storage time (days)

slide-15
SLIDE 15

Source : Ferrara, F., et al. (2012)

Antibody Library 111 scFvs 48 scFvs 14 scFvs 11 scFvs 8 scFvs

C11 and A2

Biotinylated Ag 85 + scFv Specificity test: Flow cytometry

scFv selection method

ELISA Randomly chosen

Negative control test

Top 8 clones

slide-16
SLIDE 16

scFv Selection method

Source : Ferrara, F., et al. (2012)

slide-17
SLIDE 17

Advantages of our biosensor

slide-18
SLIDE 18

Safer System

slide-19
SLIDE 19

Easily distributed

slide-20
SLIDE 20

Production Cost

slide-21
SLIDE 21

Lab Capacity

Source: http://whqlibdoc.who.int/publicatio ns/2011/9789241501330_eng.pdf

Weak / limited Sufficient

22.73%

77.27 %

slide-22
SLIDE 22

How big is the impact a better diagnostic tool will give?

slide-23
SLIDE 23

Future Direction 9 million

Source: http://www.stoptb.org/assets/documents/ne ws/Reducing%20TB%20deaths%20among%20 HIV-positives%2023nov11.pdf

6 million

slide-24
SLIDE 24

Human Practice

  • Synthetic bio club
  • Sharing with Paris Bettencourt team:

TB is a more complicated problem for woman Developing countries is not ready yet to apply synthetic biology Creation of safer system to apply synthetic biology in developing countries is needed

slide-25
SLIDE 25

Parts Submitted

  • BBa_K1182425 Split β-Galactosidase α Fragment [improvement of

BBa_K823016]

  • BBa_K1182000 Split β-Galactosidase ω Fragment [improvement of

BBa_K891003]

  • BBa_K1182007 Antigen85-Biosensor α Fragment
  • BBa_K1182008 Antigen85-Biosensor ω Fragment
  • BBa_K1182010 (G4S)4 Linker
  • BBa_K1182011 Loxp511 Linker
  • BBa_K1182401 Forward Primer β-Galactosidase ω Fragment
  • BBa_K1182501 Reverse Primer β-Galactosidase ω Fragment
slide-26
SLIDE 26

Sponsors